The effect of Deluxitine on the negative symptoms of schizophrenia

The effects of Duloxetine adjuantive treatment on Negative Symptoms of Schizophrenia

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT20191218045795N2

Enrollment

Registered

2020-04-04

Start date

2019-09-23

Completion date

Unknown

Last updated

2020-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Negative symptom.

Interventions

Intervention 1: Intervention group: Deloxitin powder, manufactured by Dana Gostar Pharmaceuticals and weighed with 10 mg precision scales, is poured into the empty capsules. Patients receive 30 mg of

Eligibility

Sex/Gender

All

Age

18 Years to 59 Years

Inclusion criteria

Inclusion criteria: Patients with schizophrenia Patients with prominent negative symptoms

Exclusion criteria

Exclusion criteria: major depression

Design outcomes

Primary

Measure	Time frame
Comparison of the positive and negative symptoms of schizophrenia. Timepoint: At baseline, 2, 4 and 8 weeks later. Method of measurement: Questionnaire for comparing positive and negative symptoms.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNarges Shams Alizadeh

Sanandaj University of Medical Sciences

n.shamsalizadeh@muk.ac.ir+98 87 3366 0026

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026